The estimated Net Worth of Julien L Pham is at least 240$ dollars as of 30 July 2018. Julien Pham owns over 500 units of Genprex Inc stock worth over 240$ and over the last 6 years Julien sold GNPX stock worth over 0$.
Julien has made over 1 trades of the Genprex Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Julien bought 500 units of GNPX stock worth 1,700$ on 30 July 2018.
The largest trade Julien's ever made was buying 500 units of Genprex Inc stock on 30 July 2018 worth over 1,700$. On average, Julien trades about 167 units every 0 days since 2018. As of 30 July 2018 Julien still owns at least 500 units of Genprex Inc stock.
You can see the complete history of Julien Pham stock trades at the bottom of the page.
Julien's mailing address filed with the SEC is 1601 Trinity St Bldg. A, Austin, TX 78712, USA.
Over the last 7 years, insiders at Genprex Inc have traded over 0$ worth of Genprex Inc stock and bought 156,300 units worth 607,092$ . The most active insiders traders include Ryan M. Confer、Christy M. Nance、Jack A Roth. On average, Genprex Inc executives and independent directors trade stock every 205 days with the average trade being worth of 14,575$. The most recent stock trade was executed by John Rodney Varner on 21 April 2023, trading 19,000 units of GNPX stock currently worth 20,140$.
genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur
Genprex Inc executives and other stock owners filed with the SEC include: